Abstract

The aim of the review is the coverage of recent open literature (2007-2009) on thiadiazole-containing bioactive compounds. Reviews sections are organized on the basis of the biological activities (antitumorals, antibacterial, antifungal agents, analgesics, etc.).

Keywords: Heterocycles, thiadiazole, biologically active compounds, Acetazolamide, Methazolamide, Chagas' disease, Trypanosoma cruzi, Megazol, E. coli, Salmonella typhosa, Staphococcus aureas, cephalosporin, Ceftobiprole Medocaril, Cefclidin, L. major, nitrofuran, nitrothiophene, Brazilizone A, Megazol (5), 3D-QSAR models, Leishmania, Helicobacter pylori, Metronidazole, Bacillus antracis, Bacillus cereus, Sarcina lutea, K. pneumonia, Rhizopus, M. gypsuem, Fluconazole, Ciprofloxacin, Gatifloxacin, C.diphtheriae, S. cerevisiae, P. aeruginosa, Ampicillin, Candida-resistant strains, Candida albicans, Aspergillus niger, NSAIDs, COX, aspirin, diclofenac, ibuprofen, Celecoxib, Rofecoxib, triazolo-thiadiazole system, Valdecoxib, DuP-697, lipid peroxidation, Naproxen, SO2NH2, NNRTIs, sulfanyltetrazole, Antitumorals, FABT, medulloblastoma, rhabdosarcoma, neuroblastoma, Preliminary bioassay, Aminopeptidase N, VEGF, KDR, PPARs, metabolic syndrome, Alzheimer's disease, Parkinson's disease, multiple sclerosis, glaucoma, Necroptosis, apoptosis, ischemia, necrostatins, Rimonabant, aquaporin 4 (AQP4), Creutzfeldt, –, Jakob disease